The online version of this article (doi:10.1186/1477-7819-10-60) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
WD and Q-jZ designed the study and wrote the article. WD and J-rZ conducted the experiments and carried out the statistical analyses. D-lW and KG assisted with experiments and manuscript preparation. All authors read and approved the final manuscript.
The combined effects of anticancer drugs with nutritional factors against tumor cells have been reported previously. This study characterized the efficacy and possible mechanisms of the combination of sorafenib and vitamin K1 (VK1) on glioma cell lines.
We examined the effects of sorafenib, VK1 or their combination on the proliferation and apoptosis of human malignant glioma cell lines (BT325 and U251) by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, flow cytometry and 4′,6-diamidino-2-phenylindole (DAPI) assay. The signaling pathway changes were detected by western blotting.
Sorafenib, as a single agent, showed antitumor activity in a dose-dependent manner in glioma cells, but the effects were more pronounced when used in combination with VK1 treatment. Sorafenib in combination with VK1 treatment produced marked potentiation of growth inhibition and apoptosis, and reduced expression of phospho-mitogen-activated protein kinase kinase (MEK) and phospho-extracellular signal-regulated kinase (ERK). Furthermore, the expression levels of antiapoptotic proteins Bcl-2 and Mcl-1 were significantly reduced.
Our findings indicated that VK1 enhanced the cytotoxicity effect of sorafenib through inhibiting the Raf/MEK/ERK signaling pathway in glioma cells, and suggested that sorafenib in combination with VK1 maybe a new therapeutic option for patients with gliomas.
Authors’ original file for figure 112957_2011_1065_MOESM1_ESM.tiff
Authors’ original file for figure 212957_2011_1065_MOESM2_ESM.tiff
Authors’ original file for figure 312957_2011_1065_MOESM3_ESM.tiff
Authors’ original file for figure 412957_2011_1065_MOESM4_ESM.tiff
Authors’ original file for figure 512957_2011_1065_MOESM5_ESM.tiff
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64: 7099-7109. 10.1158/0008-5472.CAN-04-1443. CrossRefPubMed
Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA, New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium: Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol. 2011, 13: 1324-1330. 10.1093/neuonc/nor145. PubMedCentralCrossRefPubMed
Krueger T, Westenfeld R, Schurgers L, Brandenburg V: Coagulation meets calcification: the vitamin K system. Int J Artif Organs. 2009, 32: 67-74. PubMed
Okayasu H, Ishihara M, Satoh K, Sakagami H: Cytotoxic activity of vitamins K1, K2 and K3 against human oral tumor cell lines. Anticancer Res. 2001, 21: 2387-2392. PubMed
Huang CS, Lyu SC, Hu ML: Synergistic effects of the combination of beta-ionone and sorafenib on metastasisof human hepatoma SK-Hep-1 cells. Invest New Drugs. in press
Roy CS, Karmakar S, Banik NL, Ray SK: Synergistic efficacy of sorafenib and genistein in growth inhibition by downregulating angiogenic and survival factors and increasing apoptosis throughupregulation of p53 and p21 in malignant neuroblastoma cells having N-Mycamplification or non-amplification. Invest New Drugs. 2010, 28: 812-824. 10.1007/s10637-009-9324-7. CrossRef
- Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II